Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. Kaufman M, Pardo G, Rossman H, Sweetser MT, Forrestal F, Duda P J Neurol Sci. 2014 Mar 26. PMID: 24731783. Abstract CommentRecommendBookmarkWatch